The notices it replaced
- Reissues: PAR-19-363 Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)
- 2 steps back: PAR-18-629
Replaced by PAR-25-175.
Who won it before
13 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $8,159,154 in first-year total cost, median $670,223.
Most frequent study sections
- Clinical Translational Imaging Science Study Section[CTIS]10
- Special Emphasis Panel[ZRG1 CTIS-C (07)]1
- Special Emphasis Panel[ZRG1 ISB-N (03)]1
- Special Emphasis Panel[ZRG1 SBIB-Q (03)]1
Most frequent institutions
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2
- UNIVERSITY OF WASHINGTON2
- JOHNS HOPKINS UNIVERSITY1
- MASSACHUSETTS GENERAL HOSPITAL1
- QUEEN'S MEDICAL CENTER1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Integration of circulating tumor cell and nuclear imaging biomarkers to assess LuPSMA response and resistance in advanced prostate cancer patients1R01CA302774-01 | MIYAMOTO, DAVID T.NG, SHEUNG CHEE THOMAS | MASSACHUSETTS GENERAL HOSPITAL, MA | $684,107 | CTIS |
| 2025 | Longitudinal Imaging and Liquid Biopsy Markers of Prostate Cancer Radiotherapy Outcomes1R01CA294824-01A1 | POLLACK, ALANSPIELER, BENJAMIN ORENSTOYANOVA, RADKA | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, FL | $538,553 | ZRG1 |
| 2024 | A framework for integrating MR imaging and clinical tests for prediction of outcomes in multiple myeloma treatment1R01CA278898-01A1 | DONG, QIANZHOU, CHUAN | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $577,373 | CTIS |
| 2023 | Integrating liquid biopsy-based epigenetic and imaging modalities to evaluate disease response in multiple myeloma1R01CA280637-01 | CHIU, BRIAN C-HDERMAN, BENJAMINZHANG, WEI | UNIVERSITY OF CHICAGO, IL | $691,734 | CTIS |
| 2023 | Integrating circulating tumor DNA assay and protein-based MRI to accurately monitor glioma therapy1R01CA276221-01A1 | BETTEGOWDA, CHETANJIANG, SHANSHAN | JOHNS HOPKINS UNIVERSITY, MD | $691,360 | CTIS |
| 2023 | Integrated blood and radiomic subtyping to guide immunotherapy treatment selection and early response assessment in metastatic non-small cell lung cancer1R01CA276178-01A1 | VOKES, NATALIEWU, JIA | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $676,561 | CTIS |
| 2022 | Integration of Imaging and Circulating Plasma Cell-Free DNA Sequencing Using MSK-ACCESS to Monitor Treatment Response and Predict Progression in Patients With Multiple Cancers on Targeted Therapy1R01CA273224-01 | BERGER, MICHAEL F.DRILON, ALEXANDERGINSBERG, MICHELLE | SLOAN-KETTERING INST CAN RESEARCH, NY | $734,122 | CTIS |
| 2022 | Biomarkers of Response to Immuno-chemotherapy & oliGometastatic Hypofractionated radioTherapy (BRIGHT) for Lung Cancer: Synergy of PET/CT Imaging and Peripheral Blood Assays1R01CA258997-01A1 · under PAR-19-363 | BOWEN, STEPHEN R.ZENG, JING | UNIVERSITY OF WASHINGTON, WA | $622,286 | CTIS |
| 2021 | Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancer1R01CA257610-01 · under PAR-19-363 | DUDDALWAR, VINAYGOLDKORN, AMIRTRICHE, TIMOTHY J. | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $706,071 | ZRG1 |
| 2021 | Strategy for combining circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) measures of tumor burden for prediction of response and outcome in neoadjuvant-treated early breast cancer1R01CA255442-01 · under PAR-19-363 | LI, WENMAGBANUA, MARK JESUSVAN'T VEER, LAURA J | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $670,223 | CTIS |
| 2021 | Optimizing Pancreatic Cancer Management with Next Generation Imaging and Liquid Biopsy1R01CA256969-01 · under PAR-19-363 | COLLISSON, ERICGOENKA, AJIT HARISHKUMARWANG, ZHEN JANE | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $624,558 | CTIS |
| 2021 | Evaluation of treatment predictors reflecting beta-catenin activation in hepatocellular carcinoma1R01CA262460-01 · under PAR-19-363 | KWEE, SANDI ALEXANDER | QUEEN'S MEDICAL CENTER, HI | $520,008 | CTIS |
| 2021 | Role of ctDNA change as a response measure in the EA1183 patient population and how ctDNA changes correlate with metabolic response by serial FDG PET/CT1R01CA251803-01A1 · under PAR-19-363 | SPECHT, JENNIFER MARIE | UNIVERSITY OF WASHINGTON, WA | $422,198 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.